210826-40-7

Basic information

• Product Name: MCC950
• Synonyms: MCC950;CP-456773;N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide;N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamid
• CAS NO: 210826-40-7
• Molecular Formula: C20H24N2O5S
• Molecular Weight: 404.49
• EINECS: 604-604-1
• Mol File: 210826-40-7.mol

Chemical Properties

• Melting Point: 239 °C
• Appearance: /
• Density: 1.396±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml)
• PKA: 4.74±0.10(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month.
• CAS DataBase Reference: MCC950(CAS DataBase Reference)
• NIST Chemistry Reference: MCC950(210826-40-7)
• EPA Substance Registry System: MCC950(210826-40-7)

Safety Data

• Hazardous Substances Data: 210826-40-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
MCC950 is used as an inhibitor of the NLRP3 inflammasome for its potential therapeutic effects on a wide range of immune disorders. These disorders include multiple sclerosis, inflammatory bowel disease, and various auto-immune and auto-inflammatory diseases. By specifically inhibiting the activation of NLRP3, MCC950 can help modulate the inflammatory response and alleviate the symptoms associated with these conditions.
Used in Research and Development:
MCC950 is used as a valuable tool in research and development for exploring the pathophysiology of NLRP3. Its ability to selectively inhibit the NLRP3 inflammasome, without affecting other inflammasomes such as AIM2, NLRC4, or NLRP1, makes it an ideal candidate for studying the specific roles and interactions of NLRP3 in various biological processes and disease states.
Used in Drug Delivery Systems:
MCC950 can be employed in the development of novel drug delivery systems to enhance its therapeutic potential and bioavailability. By incorporating MCC950 into various organic and metallic nanoparticles, researchers can improve its delivery to target cells and tissues, potentially leading to more effective treatments for NLRP3-associated syndromes.

References

1) Laliberte?et al.?(2003),?Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem.,?278?16567 2) Coll?et al. (2011),?The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One,?6(12)?e29539 3) Coll?et al.?(2015),?A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med.,?21?248 4) Kaneko?et al.?(2015),?Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods,?426?76

Upstream product

• 496-11-7 INDANE 
• 14927-64-1 3,5,6,7-tetrahydro-2H-s-indacen-1-one 
• 39105-39-0 3-chloro-1-(2,3-dihydro-1H-inden-5-yl)propan-1-one 
• 63089-56-5 1,2,3,5,6,7-hexahydro-s-indacen-4-yl-amine 
• 210827-31-9 4-isocyanato-1,2,3,5,6, 7-hexahydro-s-indacene 
• 210827-34-2 4-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide 

Relevant articles and documents

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl) furan-2-sulfonyl]urea, An anti-inflammatory agent

A novel synthesis of the anti-inflammatory agent 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)- furan-2-sulfonyl]urea 1 is described. Sulfonamide 5 was prepared starting from ethyl 3-furoate 2. Key steps were a one-pot sulfonylation with chlorosulfonic acid in methylene chloride followed by pyridinium salt formation and reaction with phosphorus pentachloride to provide ethyl 2-(chlorosulfonyl)-4-furoate 7. This sulfonyl chloride was treated with ammonium bicarbonate to form sulfonamide 8, followed by treatment with excess methyl magnesium chloride to provide 4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonamide 5. 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene 16 was prepared from indan in five steps. The formation of the desired sulfonyl urea was carried out both with the isolated isocyanate 16 and via an in situ method.

Sulfonyl urea derivatives and their use in the control of interleukin-1 activity

PCT No. PCT/IB97/01603 Sec. 371 Date Jul. 16, 1999 Sec. 102(e) Date Jul. 16, 1999 PCT Filed Dec. 29, 1997 PCT Pub. No. WO98/32733 PCT Pub. Date Jul. 30, 1998A compound of formula (I) wherein R1 and R2 are as defined in the description, R2 being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including human.